Decided to do a quick valuation model. Notes below
Only considers VP-001. No value assigned to pipeline nor platform.
All figures USD
Addressable market (annual) - 1 billion p.a.
Probability of FDA approval - 65% (based on PYC presentation citing monogenic disease target drugs)
Additional development cost - $50m (excludes current cash on hand)
Years to market - 3 years
Discount rate - 10% (appropriate as its very stable cashflow once FDA approved. Probability of approval already included above)
Years of patent protection from today - 17 years
NPV - $2.9 bn USD
If I reduce probability of FDA approval to 10%, we still get a valuation of $450m USD
With a current market cap of $150m USD, PYC is very undervalued. Of course this may reflect the binary nature of potential outcomes (drugs can either get approved, or get rejected)
- Forums
- ASX - By Stock
- PYC
- New valuation of PYC
New valuation of PYC
-
- There are more pages in this discussion • 27 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PYC (ASX) to my watchlist
|
|||||
Last
13.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $606.5M |
Open | High | Low | Value | Volume |
13.5¢ | 13.5¢ | 12.5¢ | $17.86K | 137.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
11 | 1081168 | 12.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
13.0¢ | 505604 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
10 | 1069168 | 0.125 |
11 | 1346557 | 0.120 |
12 | 1239403 | 0.115 |
10 | 403370 | 0.110 |
13 | 1221009 | 0.105 |
Price($) | Vol. | No. |
---|---|---|
0.135 | 537674 | 5 |
0.140 | 1117191 | 5 |
0.145 | 256800 | 2 |
0.150 | 525000 | 3 |
0.165 | 23000 | 1 |
Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
Featured News
PYC (ASX) Chart |